UPC2 is universally essential for azole antifungal resistance in Candida albicans

Eukaryotic Cell

Volumn 13, Issue 7, 2014, Pages 933-946

  Vasicek, Erin M ^a   Berkow, Elizabeth L ^a   Flowers, Stephanie A ^a   Barker, Katherine S ^a   David Rogers, P ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FUNGAL PROTEIN; TRANSCRIPTION FACTOR;

ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; DRUG EFFECTS; GENETICS; METABOLISM;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; TRANSCRIPTION FACTORS;

EID: 84903648333     PISSN: 15359778     EISSN: None     Source Type: Journal    
DOI: 10.1128/EC.00221-13     Document Type: Article

References (53)

1. Pfaller MA, Sheehan DJ, Rex JH. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268-280. http://dx.doi.org/10.1128/CMR.17.2.268-280.2004.
2. Marie C, White TC. 2009. Genetic basis of antifungal drug resistance. Curr. Fungal Infect. Rep. 3:163-169. http://dx.doi.org/10.1007/s12281-009-0021-y.
3. Sussman A, Huss K, Chio LC, Heidler S, Shaw M, Ma D, Zhu G, Campbell RM, Park TS, Kulanthaivel P, Scott JE, Carpenter JW, Strege MA, Belvo MD, Swartling JR, Fischl A, Yeh WK, Shih C, Ye XS. 2004. Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening. Eukaryot. Cell 3:932-943. http://dx.doi.org/10.1128/EC.3.4.932-943.2004.
4. Lewis RE, Rogers PD. 2007. Opportunistic mycoses, p 1600. In Chisholm-Burns M, Wells B, Schwinghammer T, Malone P, Kolesar J, Rotschafer J, DiPiro J. (ed), Pharmacotherapy principles and practice, 1st ed. McGraw-Hill Medical, New York, NY.
5. Jarvis WR. 1995. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20:1526-1530. http://dx. doi.org/10.1093/clinids/20.6.1526.
6. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177. http: //dx.doi.org/10.1086/378745.
7. Silverman S, Jr, Gallo JW, McKnight ML, Mayer P, deSanz S, Tan MM. 1996. Clinical characteristics and management responses in 85 HIVinfected patients with oral candidiasis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 82:402-407. http://dx.doi.org/10.1016/S1079-2104 (96)80304-0.
8. Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W, Jr, Lang W, Samuel M, Buchbinder SP, Hessol NA, Lifson AR, Rutherford GW, Moss A, Osmond D, Shiboski S, Greenspan JS. 1991. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 5:519-525. http://dx.doi. org/10.1097/00002030-199105000-00007.
9. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354-358. http://dx.doi.org/10.1056/NEJM198408093110602.
10. Kontoyiannis DP, Lewis RE. 2002. Antifungal drug resistance of pathogenic fungi. Lancet 359:1135-1144. http://dx.doi.org/10.1016/S0140-6736 (02)08162-X.
11. Traeder C, Kowoll S, Arasteh K. 2008. Candida infection in HIV positive patients 1985-2007. Mycoses 51(Suppl 2):58-61. http://dx.doi.org/10. 1111/j.1439-0507.2008.01574.x.
12. Ghannoum MA, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:501-517.
13. Hitchcock CA, Whittle PJ. 1993. Chemistry and mode of action of fluconazole, p 183-197. In Rippon JW, Fromtling RA (ed), Cutaneous antifungal agents: selected compounds in clinical practice and development. Marcel Dekker, Inc, New York, NY.
14. Levin DE. 2005. Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 69:262-291. http://dx.doi.org/10.1128/MMBR. 69.2.262-291.2005.
15. Anderson JB. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3:547-556. http://dx.doi.org /10.1038/nrmicro1179.
16. Sanglard D. 2003. Resistance and tolerance mechanisms to antifungal drugs in fungal pathogens. Mycologist 17(2):74-78. http://dx.doi.org/10. 1017/S0269915X03002076.
17. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. 1994. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:2092-2098.
18. White TC, Marr KA, Bowden RA. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
19. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49:1745-1752. http://dx.doi.org/10.1128 /AAC.49.5.1745-1752.2005.
20. Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aid M, Boucher G, Rogers PD, Raymond M, Morschhäuser J. 2011. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob. Agents Chemother. 55:2212-2223. http://dx.doi.org/10.1128/AAC.01343-10.
21. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14-α-methylergosta-8,24(28)-dien-3-β,6-α-diol. Biochem. Biophys. Res. Commun. 207:910-915. http://dx.doi.org/10.1006/bbrc.1995.1272.
22. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. NCCLS, Wayne, PA.
23. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
24. Reuss O, Vik A, Kolter R, Morschhäuser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. http://dx.doi.org/10.1016/j.gene.2004.06.021.
25. Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell 7:1180-1190. http://dx.doi.org/10.1128/EC.00103-08.
26. Amberg DC, Burke DJ, Strathern JN. 2006. Isolation of yeast genomic DNA for Southern blot analysis. CSH Protoc. 2006:pii:pdb. prot4149. http://dx.doi.org/10.1101/pdb.prot4149.
27. Schmitt ME, Brown TA, Trumpower BL. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092. http://dx.doi.org/10.1093/nar/18.10.3091.
28. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot. Cell 11:1289-1299. http://dx.doi.org /10.1128/EC.00215-12.
29. Znaidi S, Weber S, Al-Abdin OZ, Bomme P, Saidane S, Drouin S, Lemieux S, De Deken X, Robert F, Raymond M. 2008. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot. Cell 7:836-847. http://dx.doi. org/10.1128/EC.00070-08.
30. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652. http://dx.doi.org/10.1128/EC.3.6. 1639-1652.2004.
31. Morschhäuser J, Barker KS, Liu TT, Blaß-Warmuth J, Homayouni R, Rogers PD. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164. http://dx.doi.org/10.1371/journal.ppat. 0030164.
32. Sasse C, Schillig R, Dierolf F, Weyler M, Schneider S, Mogavero S, Rogers PD, Morschhäuser J. 2011. The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans. PLoS One 6:e25623. http://dx.doi.org/10.1371 /journal.pone.0025623.
33. Schubert S, Popp C, Rogers PD, Morschhäuser J. 2011. Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. Eukaryot. Cell 10:1110-1121. http://dx. doi.org/10.1128/EC.05100-11.
34. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FC, Odds FC, Bossche HV. 1999. Contribution of mutations in the cytochrome P450 14-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145(Part 10):2701-2713.
35. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713. http://dx.doi.org/10.1128/AAC.46.6. 1704-1713.2002.
36. Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3:1391-1397. http://dx.doi.org/10.1128/EC.3.6.1391-1397. 2004.
37. Oliver BG, Song JL, Choiniere JH, White TC. 2007. cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p. Eukaryot. Cell 6:2231-2239. http: //dx.doi.org/10.1128/EC.00331-06.
38. Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J. 2010. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob. Agents Chemother. 54:353-359. http://dx.doi. org/10.1128/AAC.01102-09.
39. Hoot SJ, Smith AR, Brown RP, White TC. 2011. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 55: 940-942. http://dx.doi.org/10.1128/AAC.00995-10.
40. White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
41. Rogers PD, Barker KS. 2003. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 47:1220-1227. http://dx.doi.org/10.1128/AAC.47.4. 1220-1227.2003.
42. Sasse C, Dunkel N, Schafer T, Schneider S, Dierolf F, Ohlsen K, Morschhäuser J. 2012. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol. Microbiol. 86:539-556. http://dx.doi.org/10.1111/j.1365-2958.2012.08210.x.
43. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U, Einsele H. 1997. Resistance to fluconazole and crossresistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol 5,6-desaturation. FEBS Lett. 400:80-82. http: //dx.doi.org/10.1016/S0014-5793(96)01360-9.
44. Klepser ME. 2006. Candida resistance and its clinical relevance. Pharmacotherapy 26:68S-75S. http://dx.doi.org/10.1592/phco.26.6part2.68S.
45. Watson PF, Rose ME, Ellis SW, England H, Kelly SL. 1989. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. 164:1170-1175. http://dx.doi.org/10.1016/0006-291X(89)91792-0.
46. Henry KW, Nickels JT, Edlind TD. 2000. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 44:2693-2700. http://dx.doi.org/10.1128 /AAC.44.10.2693-2700.2000.
47. Prasad T, Chandra A, Mukhopadhyay CK, Prasad R. 2006. Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drugsusceptible cells. Antimicrob. Agents Chemother. 50:3597-3606. http://dx. doi.org/10.1128/AAC.00653-06.
48. Kuipers ME, Beljaars L, Van Beek N, De Vries HG, Heegsma J, Van Den Berg JJ, Meijer DK, Swart PJ. 2002. Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida. Impact on the development of buccal preparations of lactoferrin. APMIS 110:290-298. http://dx.doi.org/10.1034/j. 1600-0463.2002.100403.x.
49. Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. 1999. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. 43:2635-2641.
50. Venkatesh MP, Rong L. 2008. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J. Med. Microbiol. 57:1113-1121. http://dx.doi.org/10. 1099/jmm.0.2008/001263-0.
51. Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Rolley N, Kelly DE, Kelly SL. 2010. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54:4527-4533. http://dx.doi.org/10.1128/AAC.00348-10.
52. Kim J, Cho YJ, Do E, Choi J, Hu G, Cadieux B, Chun J, Lee Y, Kronstad JW, Jung WH. 2012. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs. Fungal Genet. Biol. 49:955-966. http://dx.doi.org/10.1016/j.fgb.2012.08.006.
53. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, Pfaller M. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242. http://dx.doi.org/10.1093/clinids/18.2. 240.